Arterial hypertension: a complete guide

01Understanding arterial hypertension, the "silent killer"#

Arterial hypertension (HTN) is one of the most common chronic diseases in the world and in Morocco, and yet it remains one of the most under-diagnosed and under-treated. Medically, it is defined as persistent elevation of blood pressure in the arteries, measured repeatedly above the thresholds set by international scientific societies. This chronic pressure rise progressively damages arterial walls and every organ that depends on them — heart, brain, kidneys, eyes — hence its severity when left untreated.

HTN is nicknamed the "silent killer" because it usually progresses without any obvious symptoms for years, even decades, until a serious complication occurs. The first signs may be a stroke, a heart attack, kidney failure or vision loss — events that could have been prevented by early screening and treatment. This silent nature explains why millions of people are unaware they are hypertensive and why simply measuring blood pressure regularly is probably the most cost-effective preventive health gesture in adult life.

In Morocco, according to the National Survey on Risk Factors (ENFR) by the Ministry of Health and the World Health Organization, about 30% of Moroccan adults suffer from hypertension, or roughly 8 million people. Prevalence rises sharply with age: less than 10% before 40, nearly 50% after 60 and over 70% after 75. HTN is more common in urban than rural settings and affects men and women similarly with age-related particularities. The most worrying observation is that fewer than 50% of hypertensive Moroccans are diagnosed, and among those diagnosed, fewer than 30% have their blood pressure properly controlled — a vast public-health improvement opportunity.

02Normal and pathological blood-pressure numbers#

Blood pressure is expressed by two numbers with distinct physiological meanings. Systolic pressure, the higher number, corresponds to the maximum pressure in the arteries when the heart contracts (systole) and ejects blood into the circulation. Diastolic pressure, the lower number, corresponds to the minimum pressure between contractions when the heart relaxes and refills (diastole). Both values matter and either can be abnormal.

The thresholds set by the WHO, the European Society of Cardiology (ESC) and the Moroccan Society of Cardiology in the medical office are as follows.

A single elevated reading is never enough to diagnose hypertension. Several phenomena can transiently raise blood pressure without true disease: white-coat syndrome (15–30% of patients), pain, recent exertion, recent intense physical activity, intake of certain substances (caffeine, alcohol, tobacco within 30 minutes), or talking during the measurement. Diagnosis therefore requires several measurements taken under standardised conditions over several weeks.

Home self-measurement is now the reference method for confirming HTN suspected in the office. It is performed with a validated upper-arm electronic monitor (not a wrist device, which is less reliable), at home in calm conditions, seated, after 5 minutes of rest, with three consecutive measurements in the morning before medication and three in the evening, for 7 consecutive days. An average greater than or equal to 135/85 mmHg confirms hypertension. Monitors are available in Moroccan pharmacies for 400 to 800 MAD depending on the model — a worthwhile investment for long-term follow-up.

24-hour ambulatory blood pressure monitoring (ABPM) is the most precise test: it uses an automatic cuff measuring blood pressure every 15 to 30 minutes for 24 hours, day and night, providing a complete map of pressure variations including the nocturnal profile (essential — absence of nocturnal dipping is a poor prognostic factor). It is indicated when there is diagnostic doubt, resistant hypertension, discrepancy between office and home readings, or to assess the efficacy of a difficult-to-balance regimen. Cost in Morocco: 800 to 1,500 MAD, partially reimbursed by AMO on cardiology prescription.

03Symptoms of HTN, often absent#

HTN is generally asymptomatic, which makes active screening all the more important. More than half of hypertensive individuals are unaware of their condition before routine screening or a complication. This does not mean elevated pressure has no consequences — on the contrary, it silently damages arteries and organs throughout the asymptomatic period.

When symptoms exist, they are variable and non-specific. Headaches, particularly morning, occipital, sometimes pulsatile, are classically described, although their direct link to HTN is debated outside major pressure surges. Dizziness, tinnitus, recurrent nosebleeds (epistaxis) are sometimes reported. Blurred vision, floaters or flashes of light may indicate hypertensive retinopathy and require a fundus exam. Palpitations, progressive exertional dyspnoea, ankle oedema may indicate early cardiac involvement.

The acute hypertensive crisis (sudden rise above 180/120 mmHg with symptoms) is a medical emergency justifying a 141 call. It manifests as severe headache, nausea and vomiting, confusion, visual disturbances, sometimes chest pain or major dyspnoea, and even seizures or focal neurological deficit if a stroke accompanies it. Emergency management aims to lower blood pressure in a controlled fashion (without dropping too quickly, which could paradoxically cause an ischaemic stroke) with intravenous or oral medication depending on the picture.

04Modifiable and non-modifiable risk factors#

Several factors increase the risk of developing HTN. Identifying them helps both stratify screening and act preventively on modifiable factors.

Among non-modifiable factors, age is the most powerful: progressive arterial stiffening with ageing explains the rising prevalence after 50. First-degree family history of HTN multiplies risk by 2 to 3, due to the genetic component (heritability estimated at 30–50%). Ethnic origin plays a role; HTN is more frequent and earlier in African and Afro-Caribbean populations, which partially concerns the Moroccan population. Male sex is associated with higher prevalence before 60, but this difference reverses after menopause when women catch up and surpass men due to the loss of oestrogenic protection.

Among modifiable factors, several are particularly relevant in Morocco. Excessive salt consumption is probably the most important factor at population level: the WHO recommends less than 5 grams of salt per day, about a teaspoon. Average consumption in Morocco is around 10 to 12 grams per day, more than double the recommendation, due to abundant salt use in traditional cooking, large bread consumption (very salty industrially), preserves, processed meats, salty cheeses, ready meals and sauces. Cutting salt by 5 grams per day would lower systolic pressure by 5 to 7 mmHg on average — equivalent to one antihypertensive drug.

Overweight and obesity are major risk factors: each 10 kg of excess weight adds about 5 to 10 mmHg to blood pressure. Sedentary behaviour (less than 150 minutes of moderate physical activity per week) roughly doubles HTN risk. Excessive alcohol consumption beyond 2 standard drinks per day raises pressure dose-dependently. Tobacco use does not directly cause chronic HTN but causes transient rises with each cigarette and massively increases overall cardiovascular risk. Chronic psychological stress, particularly when accompanied by sleep disorders or poorly managed anxiety, also contributes to HTN.

Several comorbidities are frequently associated with HTN: type 2 diabetes (HTN is present in 60–70% of patients with diabetes), often-undiagnosed obstructive sleep apnoea syndrome, chronic kidney disease, and rare endocrine pathologies (primary hyperaldosteronism, phaeochromocytoma, Cushing's syndrome) which should be considered in young or resistant hypertensive patients. Several medications can raise pressure: chronic NSAID use, some antidepressants, oestrogen-progestin contraceptives, corticosteroids and certain nasal decongestants.

05Feared complications of untreated HTN#

Uncontrolled HTN progressively damages several target organs, with major clinical consequences that fully justify the therapeutic effort. In Morocco, HTN is responsible for the bulk of cardiovascular mortality and represents the leading indirect cause of death in the country.

Stroke is the most feared complication. Chronic HTN weakens cerebral arteries, promotes their sclerosis and the formation of small aneurysms, and can lead to either ischaemic stroke (arterial occlusion, 80% of cases) or haemorrhagic stroke (vascular rupture, 20%, but more deadly). Stroke is now the leading cause of acquired disability in Morocco and the second leading cause of death after cardiac disease. Lowering blood pressure by 10 mmHg on average reduces stroke risk by 30 to 40%.

Myocardial infarction and coronary artery disease are also strongly aggravated by HTN, which accelerates coronary atherosclerosis. Heart failure through left ventricular hypertrophy and then dilatation is a progressive complication. Atrial fibrillation, the most common cardiac rhythm disorder, is favoured by HTN and itself increases stroke risk.

Chronic kidney disease, through progressive nephroangiosclerosis, is one of the leading causes of CKD in Morocco, accounting for 25% of dialysis cases. Hypertensive retinopathy through damage to retinal arterioles can lead to vision loss in severe forms. Vascular dementia and cognitive disorders through repeated micro-strokes are late but disabling complications. Aortic aneurysm and dissection are rare but dramatic complications. Peripheral arterial disease of the lower limbs through accelerated atherosclerosis can lead to amputation in advanced cases.

06Treating HTN: lifestyle first#

Management of HTN rests on an indispensable lifestyle and dietary foundation, on which medication is grafted in most cases after a few months if non-pharmacological measures are insufficient. No medication exempts a patient from lifestyle measures, which remain the foundation of any sustainable treatment.

Reducing salt intake is the most effective measure, with a target of less than 5 grams per day, about a teaspoon including added kitchen salt and hidden salt in industrial foods. In practice, this means limiting industrial salty bread (preferring lower-salt or homemade bread), avoiding processed meats, very salty cheeses, preserves, commercial sauces, ready meals, salty snacks. Taste before salting, use herbs and spices for flavour, read nutrition labels. This measure lowers blood pressure by 5 to 7 mmHg on average.

Regular physical activity of at least 150 minutes per week of moderate intensity (brisk walking, swimming, cycling) lowers blood pressure by 4 to 9 mmHg. The effect is achieved after 2 to 3 months of regular practice. Weight loss in overweight hypertensive patients provides direct benefit: each kilogram lost reduces blood pressure by about 1 mmHg, and 5 to 10 kg lost can normalise early HTN. Smoking cessation does not directly lower pressure dramatically but considerably reduces overall cardiovascular risk. Moderating alcohol consumption (less than 2 drinks per day, ideally with alcohol-free days) lowers pressure in regular consumers. Stress management through validated techniques (meditation, heart-rate coherence, yoga, sophrology) provides modest but real benefit.

The DASH (Dietary Approaches to Stop Hypertension) diet, validated by numerous studies, and the Mediterranean diet, particularly suited to Moroccan culinary culture, are the two best-validated dietary models for HTN prevention and treatment. They favour fruits and vegetables (5 servings per day), whole grains, legumes, fatty fish (omega-3 sources), low-fat dairy, olive oil, nuts, and limit red meats, processed meats, processed foods, added sugars and alcohol.

07Antihypertensive medications#

When lifestyle measures are insufficient (the most common case), drug treatment is initiated. Several therapeutic classes are available in Morocco with different indications, contraindications and tolerability profiles. The initial choice depends on patient profile (age, comorbidities, tolerance) and is gradually adjusted to reach blood-pressure targets.

ACE inhibitors (ACEi) such as enalapril (Renitec, many generics), ramipril (Triatec), perindopril (Coversyl) and lisinopril are first-line options for the majority of patients. They are particularly beneficial in patients with diabetes (renoprotective effect), heart failure, after a myocardial infarction. Characteristic side effect: persistent dry cough in 10–20% of patients, justifying a switch to a sartan.

Angiotensin II receptor blockers (ARBs/sartans) — losartan (Cozaar), valsartan (Tareg), irbesartan (Aprovel), telmisartan (Micardis) — have indications very close to ACEi without the cough risk. Excellent overall tolerance.

Calcium channel blockers are represented by amlodipine (Amlor, generics) and nifedipine LA (Adalate LP), two reference molecules effective on blood pressure. Possible side effects: ankle oedema, flushing, sometimes constipation.

Thiazide diuretics (hydrochlorothiazide, indapamide/Fludex) are an old, inexpensive and effective class. Particularly useful in elderly patients and in combination with other antihypertensives. Periodic biological monitoring is necessary (kalaemia, natraemia, glycaemia).

Beta-blockers (bisoprolol/Concor, atenolol/Tenormin) are indicated first-line in hypertensive patients with coronary artery disease, heart failure or rhythm disorders. More controversial as first line in isolated HTN of young patients without comorbidities.

Other classes (alpha-blockers, central antihypertensives such as alpha-methyldopa) have more limited indications.

The monthly cost of antihypertensive treatment in Morocco ranges from 50 to 400 MAD depending on the molecules, with a wide choice of very affordable generics. HTN is on the list of Long-Term Conditions (ALD), which entitles patients to 100% reimbursement of medications on the reimbursable list. The majority of hypertensive patients require dual or triple therapy to reach pressure targets, ideally administered in fixed combinations (a single tablet containing 2 or 3 molecules) to improve adherence.

08Long-term follow-up#

Follow-up of a hypertensive patient involves regular blood-pressure measurement (weekly or fortnightly self-measurement, in-office measurement every 3 to 6 months depending on control), an annual biological work-up (creatinine and eGFR for kidney function, blood ionogram, fasting glucose, lipid panel, microalbuminuria), a baseline ECG and then every 2 years, and a fundus exam every 1 to 2 years to screen for retinopathy. Echocardiography is useful to assess possible left ventricular hypertrophy. Annual flu and pneumococcal vaccinations are recommended in hypertensive patients, particularly after 65.

Regular home self-monitoring with a validated monitor allows treatment efficacy to be tracked, helps identify drift and provides objective information to share with the doctor. Keeping a logbook or using a mobile app makes it easier to spot trends.

In Morocco, several cardiologists and general practitioners trained in HTN management work in every region. An annual cardiology consultation is recommended, complemented by close follow-up with the treating physician. Telemedicine is expanding for follow-up of stable patients, allowing more frequent checks and better treatment adjustment without travel.